Formulation and Characterization of “Ready to Use” 1B4M-DTPA-rituximab for Lu-177 Labeling

Gjorgieva Ackova, Darinka and Smilkov, Katarina and Janevik-Ivanovska, Emilija (2014) Formulation and Characterization of “Ready to Use” 1B4M-DTPA-rituximab for Lu-177 Labeling. World Journal of Medical Sciences, 11 (4). pp. 535-540. ISSN 1817-3055

[thumbnail of full text-objaveno.pdf]
full text-objaveno.pdf

Download (250kB) | Preview


Investigations for NHL treatment are oriented towards radiolabelled therapeutics. This research
focuses on formulation and characterization of a new, ready to label immunoconjugate, 1B4M-DTPA-rituximab,
which is suitable for labeling with Lu-177. The conjugation was performed using 20-fold molar excess of the
bifunctional chelating agent, 1B4M-DTPA and subsequent lyophilization. The characterization of the
(radio)immunoconjugate was performed using SE-HPLC, SDS-PAGE and MALDI-TOF-MS. The results show
that the conjugation reaction yields immunoconjugates with average of 8.3 chelating groups per one rituximab
molecule and the subsequent lyophilization did not affect the integrity, the structure, or radionuclide-binding
properties. The radiolabelling with 555 GBq/mg Lu-177 resulted in over 95% radiochemical purity, which makes
this agent a good candidate for further investigation of biological and pharmacological potency in NHL therapy.

Item Type: Article
Subjects: Medical and Health Sciences > Basic medicine
Medical and Health Sciences > Health biotechnology
Medical and Health Sciences > Other medical sciences
Divisions: Faculty of Medical Science
Depositing User: Darinka Gorgieva Ackova
Date Deposited: 25 Nov 2014 14:08
Last Modified: 25 Nov 2014 14:08

Actions (login required)

View Item View Item